Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 2/20 | 0.30 |
| ▸ | CA1 | P00915 | 2/20 | 0.30 |
| ▸ | CA2 | P00918 | 2/20 | 0.30 |
| ▸ | CA3 | P07451 | 2/20 | 0.30 |
| ▸ | CA4 | P22748 | 2/20 | 0.30 |
| ▸ | CA6 | P23280 | 2/20 | 0.30 |
| ▸ | CA5A | P35218 | 2/20 | 0.30 |
| ▸ | CA7 | P43166 | 2/20 | 0.30 |
| ▸ | CA9 | Q16790 | 2/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.30 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.30 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23761859 | 0.92 | CHRM2 (0.52) | CHRM2TDP1CYP2C9CYP2C19NFKB1 | |
| SCHEMBL24515163 | 0.91 | CHRM2 (0.52) | CHRM2TDP1 | |
| SCHEMBL23761801 | 0.90 | CHRM2 (0.56) | CHRM2NFKB1CA12CA1CA2 | |
| SCHEMBL22752564 | 0.90 | CHRM2 (0.56) | CHRM2NFKB1CA12CA1CA2 | |
| SCHEMBL1106445 | 0.82 | — | — | |
| SCHEMBL25928873 | 0.82 | ALDH1A1 (0.32) | TSHR | |
| SCHEMBL12619778 | 0.82 | ALDH1A1 (0.39) | CHRM2DNM1TSHR | |
| SCHEMBL20063347 | 0.78 | — | — | |
| SCHEMBL10805583 | 0.77 | CHRM2 (0.37) | CHRM2TDP1CYP2C9CYP2C19 | |
| SCHEMBL17493160 | 0.77 | CHRM2 (0.37) | CHRM2TDP1CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3475285-B1 | MECHANISTIC TARGET OF RAPAMYCIN SIGNALING PATHWAY INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF | SUZHOU KINTOR PHARMACEUTICALS INC (CN) | 2022-02-09 | — | — | EP | disclosed |
| US-11130737-B2 | Multifunctional aminoquinoline therapeutic agents | LOHOCLA RESEARCH CORPORATION (US) | 2021-09-28 | — | — | US | disclosed |
| US-20210276956-A1 | QUINOLINE-BASED COMPOUNDS AND METHODS OF INHIBITING CDK8/19 | UNIVERSITY OF SOUTH CAROLINA (US) | 2021-09-09 | — | — | US | disclosed |
| US-20210253535-A1 | INHIBITION OF OLIG2 ACTIVITY | Curtana Pharmaceuticals, Inc. | 2021-08-19 | — | — | US | disclosed |
| US-10391088-B2 | Analgesic compositions | LOHOCLA RESEARCH CORPORATION (US) | 2019-08-27 | — | — | US | disclosed |
| US-20190099412-A1 | ANALGESIC COMPOSITIONS | LOHOCLA RESEARCH CORPORATION | 2019-04-04 | — | — | US | disclosed |
| US-20190076539-A1 | AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 Theraprutics, Inc. (US) | 2019-03-14 | — | — | US | disclosed |
| US-9951014-B2 | Mammalian and bacterial nitric oxide synthase inhibitors | NORTHWESTERN UNIVERSITY (US) | 2018-04-24 | — | — | US | disclosed |
| US-9951014-B2 | Mammalian and bacterial nitric oxide synthase inhibitors | NORTHWESTERN UNIVERSITY (US) | 2018-04-24 | — | — | US | disclosed |
| US-20170275278-A1 | Mammalian and Bacterial Nitric Oxide Synthase Inhibitors | NORTHWESTERN UNIVERSITY (US) | 2017-09-28 | — | — | US | disclosed |
| US-20170204064-A1 | MULTIFUNCTIONAL AMINOQUINOLINE THERAPEUTIC AGENTS | LOHOCLA RESEARCH CORPORATION | 2017-07-20 | — | — | US | disclosed |
| US-20160122302-A1 | Mammalian and Bacterial Nitric Oxide Synthase Inhibitors | NORTHWESTERN UNIVERSITY | 2016-05-05 | — | — | US | disclosed |
| US-20160009733-A1 | REGULATION OF NITRIC OXIDE RELEASE AND BIOFILM DEVELOPMENT | UNIVERSITY OF WOLLONGONG (AU) | 2016-01-14 | — | — | US | disclosed |
| US-9156855-B2 | Regulation of nitric oxide release and biofilm development | Newsouth Innovation Pty Limited (AU) | 2015-10-13 | — | — | US | disclosed |
| US-20140221331-A1 | REGULATION OF NITRIC OXIDE RELEASE AND BIOFILM DEVELOPMENT | UNIVERSITY OF WOLLONGONG (AU) | 2014-08-07 | — | — | US | disclosed |
| US-8377974-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-8324257-B2 | Mitotic kinesin inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20120178733-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2012-07-12 | — | — | US | disclosed |
| US-20100041719-A1 | MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11130737-B2 | Multifunctional aminoquinoline therapeutic agents | OPRK1, OPRM1, OPRD1 | CHRM2 339/4885TDP1 1585/4885CYP2C9 3254/4885 |
| US-20210253535-A1 | INHIBITION OF OLIG2 ACTIVITY | GLI2, ING2, GMFG | CHRM2 4624/4885TDP1 3233/4885CYP2C9 4856/4885 |
| US-10391088-B2 | Analgesic compositions | OPRK1, OPRL1, OPRM1 | CHRM2 883/4885TDP1 2348/4885CYP2C9 555/4885 |
| US-20190099412-A1 | ANALGESIC COMPOSITIONS | OPRK1, OPRL1, OPRM1 | CHRM2 883/4885TDP1 2348/4885CYP2C9 555/4885 |
| US-20160122302-A1 | Mammalian and Bacterial Nitric Oxide Synthase Inhibitors | NOS1, NOS2, NOS3 | CHRM2 3907/4885TDP1 698/4885CYP2C9 1315/4885 |
| US-20170204064-A1 | MULTIFUNCTIONAL AMINOQUINOLINE THERAPEUTIC AGENTS | OPRK1, OPRM1, OPRD1 | CHRM2 313/4885TDP1 1933/4885CYP2C9 3660/4885 |
| US-20160009733-A1 | REGULATION OF NITRIC OXIDE RELEASE AND BIOFILM DEVELOPMENT | NOS1, NOS2, NOS3 | CHRM2 2289/4885TDP1 783/4885CYP2C9 2546/4885 |
| US-20120178733-A1 | FACTOR XA INHIBITORS | TFPI, F12, F11 | CHRM2 4059/4885TDP1 1080/4885CYP2C9 51/4885 |
| US-20190076539-A1 | AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | GCGR, STUB1, GID4 | CHRM2 3328/4885TDP1 3884/4885CYP2C9 3332/4885 |
| US-20100041719-A1 | MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF | KIF5B, KIF2C, KIF18B | CHRM2 4348/4885TDP1 174/4885CYP2C9 4784/4885 |
| US-20170275278-A1 | Mammalian and Bacterial Nitric Oxide Synthase Inhibitors | NOS1, NOS2, NOS3 | CHRM2 1416/4885TDP1 871/4885CYP2C9 762/4885 |
| US-20140221331-A1 | REGULATION OF NITRIC OXIDE RELEASE AND BIOFILM DEVELOPMENT | NOS1, NOS2, NOS3 | CHRM2 2289/4885TDP1 783/4885CYP2C9 2546/4885 |
| US-20210276956-A1 | QUINOLINE-BASED COMPOUNDS AND METHODS OF INHIBITING CDK8/19 | CDK8, CDK9, CDK19 | CHRM2 3919/4885TDP1 684/4885CYP2C9 1309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.